Von Hippel-Lindau (VHL) Syndrome Clinical Trials

Find Von Hippel-Lindau (VHL) Syndrome Clinical Trials Near You

A Prospective Registry for Belzutifan in the Treatment of Von Hippel-Lindau (VHL) Disease

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This study aims to evaluate the Belzutifan's efficacy, drug safety, disease course, and the health-economic impact of the treatment to Von Hippel-Lindau (VHL) syndrome.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult patients (age 18 or above) with confirmed VHL-spectrum disease through clinical and/or genetic diagnosis.

• The patient decided to use Belzutifan for their treatment.

Locations
Other Locations
Hong Kong Special Administrative Region
Prince of Wales Hospital
RECRUITING
Shatin
Contact Information
Primary
David Ka-Wai LEUNG, FRCS, MBChB
davidleung@surgery.cuhk.edu.hk
35053933
Time Frame
Start Date: 2025-12-22
Estimated Completion Date: 2029-03-31
Participants
Target number of participants: 100
Treatments
Belzutifan Group
Subjects received Belzutifan
Related Therapeutic Areas
Sponsors
Leads: Chinese University of Hong Kong

This content was sourced from clinicaltrials.gov